Tag: Biotech and Pharma

Merck announces that the US FDA has approved Keytruda (pembrolizumab) for the treatment of adult patients with locally advanced head and neck squamous cell carcinoma (HNSCC) that is resectable and PD-L1-expressing.

The U.S. Food and Drug Administration on Monday approved Merck (NSE:PROR)’s preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.

The European Medicines Agency’s safety committee has concluded that the use of Novo Nordisk’s (NOVOb.CO), popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition.

Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava in its push to expand globally.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.

Moderna (NASDAQ:MRNA) saw its shares rose nearly 5% in premarket trading Monday after the U.S. Food and Drug Administration (FDA) has approved the drugmaker’s next-generation COVID-19 vaccine, mNEXSPIKE, for adults 65 and older, as well as individuals aged 12 to 64 with at least one underlying condition that increases their risk of severe illness.

Bristol Myers Squibb has signed a partnership worth up to $11bn to develop a BioNTech cancer drug that has the potential to beat the world’s bestselling medicine Keytruda.

The U.S. Food and Drug Administration has approved British drugmaker GSK’s (GSK.L), asthma drug to treat some patients with a chronic lung disease commonly known as “smoker’s lung”, the company said on Thursday.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Telehealth company Doximity’s quarterly earnings beat wasn’t enough to offset investors’ disappointment around its guidance for the coming fiscal year.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Αύξηση κατά 32,4% παρουσιάζουν τα συνολικά κέρδη προ φόρων, τόκων και αποσβέσεων (EBITDA) του Ομίλου Lavipharm για το Α’ τρίμηνο του 2025, τα οποία διαμορφώθηκαν σε 3,77 εκατ. ευρώ έναντι 2,85 εκατ. κατά το αντίστοιχο διάστημα του προηγούμενου έτους.

Eli Lilly (LLY.N),  said on Sunday its drug Zepbound was superior to Novo Nordisk’s (NOVOb.CO),  Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

U.S. President Donald Trump plans to sign an executive order on prescription drug pricing on Monday that aims to align the United States with what other countries pay, a move he said on social media would be a cut of 59%.

Novo Nordisk NVO stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its blockbuster drugs Ozempic and Wegovy slowed, but cut its guidance for the year.

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company’s cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine.

Eli Lilly (LLY)+1.55% stock was falling early Thursday even as the drugmaker posted first-quarter earnings above analysts’ expectations, driven by higher sales of its blockbuster weight-loss drugs Zepbound and Mounjaro.

The U.S. Food and Drug Administration has approved Johnson & Johnson’s (JNJ.N),  drug to treat some patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.

Hims & Hers stock HIMS+1.39% jumped after the telehealth company that has built a business around selling copycat weight-loss drugs announced a deal with Ozempic-maker Novo Nordisk.

Pfizer PFE +0.57% reported earnings that beat Wall Street expectations early Tuesday, but said it is “unable to predict” tariff-related impacts “at this time.”